1. Market Research
  2. > Healthcare
  3. > Medical Device
  4. > In Vitro Diagnostics Market Trends
  5. > China Diagnostic Reagent Industry Report, 2013-2016

China Diagnostic Reagent Industry Report, 2013-2016

  • July 2014
  • -
  • Research In China
  • -
  • 140 pages

With the accelerated aging of the Chinese population, the increase of personal health expenditure as well as the improved medical care facilities and government health care system, China diagnostic reagent industry has been developing quickly, especially in vitro diagnostic reagents occupy over 90%. In 2013, Chinese in vitro diagnostics market size reached RMB22.98 billion, of which RMB16.61 billion came from in vitro diagnostic reagents.

Chinese in vitro diagnostic reagent market consists of biochemical diagnostic reagents, immunodiagnostic reagents and molecular diagnostic reagents. Among them, the immune reagents and biochemical reagents account for a relatively higher combined proportion, such as around 65% in 2013.

Currently, about 40%-50% share of the Chinese in vitro diagnostics market has been dominated by foreign companies represented by Roche, Siemens, Abbott and Johnson & Johnson. Although there are 300-400 local enterprises in China in vitro diagnostics industry, the top ten Chinese companies which rank by production scale only seize 30% market share, reflecting a low industry concentration degree.

Mindray Medical, KHB, Fosun Pharmaceutical, Maker Biotechnology and Da An Gene act as giants in China in vitro diagnostics industry. Especially, Mindray Medical and KHB achieved the respective in vitro diagnostics revenue of RMB2.0458 billion and RMB1.0572 billion in 2013, accounting for 13.5% of the total jointly.

In 2014, a number of local Chinese diagnostic reagent companies (including BSBE, Maker Biotechnology, Health BioMed, Wondfo, Thalys) intend to step in the capital market through IPO because they are optimistic about the prospects of the diagnostic reagent industry; the raised funds will be used in the expansion of the existing projects or the construction of new projects. SHINVA, Humanwell Healthcare and Zhongyuan Union Stem Cell Bioengineering have entered the diagnostic reagent industry through acquisitions.

The report covers the following:
Status quo of China diagnostic reagent industry, including overview, market structure, import, export, competition pattern and so on;
Development environments and trends of China diagnostic reagent industry, embracing macroeconomy, medical situation, and relevant policies;
Operation and diagnostic reagent business of 17 major companies in China diagnostic reagent industry.

Table Of Contents

China Diagnostic Reagent Industry Report, 2013-2016
1 Overview of Diagnostic Reagent Industry
1.1 Definition
1.2 Classification
1.3 Industry Chain

2 Status Quo of China Diagnostic Reagent Industry
2.1 Overview
2.2 Market Structure
2.3 Import and Export
2.3.1 Import
2.3.2 Export
2.4 Competition Pattern
2.5 Market Segments
2.5.1 Biochemical Diagnostic Reagents
2.5.2 Immunodiagnostic Reagents
2.5.3 Molecular Diagnostic Reagents
2.5.4 Comprehensive In Vitro Diagnostic Reagents

3 Development Environments and Trends of China Diagnostic Reagent Industry
3.1 Positive Factors
3.1.1 Macroeconomy
3.1.2 Medical Care
3.1.3 Policies
3.2 Trends
3.2.1 Biochemical Immunodiagnostics is still the Mainstream
3.2.2 High Industrial Concentration Degree
3.2.3 Integrated Enterprises will See Better Development

4 Major Enterprises
4.1 Shanghai Kehua Bio-engineering Co., Ltd. (KHB)
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R and D and Investment
4.1.6 Supply and Marketing
4.1.7 In Vitro Diagnostics Business
4.1.8 Anticipation and Outlook
4.2 Beijing Strong Biotechnologies, Inc (BSBE)
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R and D and Investment
4.2.6 Production and Marketing
4.2.7 Supply and Marketing
4.2.8 Anticipation and Outlook
4.3 Da An Gene
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R and D and Investment
4.3.6 Diagnostic Reagent Business
4.3.7 Supply and Marketing
4.3.8 Anticipation and Outlook
4.4 Fosun Pharmaceutical
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R and D and Investment
4.4.6 Diagnostic Reagent Business
4.4.7 Anticipation and Outlook
4.5 Beijing Leadman Biochemistry Co., Ltd.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 R and D and Investment
4.5.6 Clients
4.5.7 Anticipation and Outlook
4.6 Livzon Pharmaceutical Group Inc.
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R and D
4.6.6 Diagnostic Reagent Business
4.6.7 Anticipation and Outlook
4.7 Mindray Medical
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 R and D and Investment
4.7.6 Diagnostic Reagent Business
4.7.7 Anticipation and Outlook
4.8 Biosino Bio-Technology and Science Inc.
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 Anticipation and Outlook
4.9 Maker Biotechnology
4.9.1 Profile
4.9.2 Operation
4.9.3 Revenue Structure
4.9.4 Gross Margin
4.9.5 R and D and Investment
4.9.6 Supply and Marketing
4.9.7 Production and Marketing
4.9.8 Anticipation and Outlook
4.10 Sinocare
4.10.1 Profile
4.10.2 Operation
4.10.3 Revenue Structure
4.10.4 Gross Margin
4.10.5 Anticipation and Outlook
4.11 Beijing Kinghawk Pharmaceutical Co., Ltd.
4.11.1 Profile
4.11.2 Operation
4.11.3 Revenue Structure
4.11.4 Gross Margin
4.11.5 Anticipation and Outlook
4.12 Bohui Innovation
4.12.1 Profile
4.12.2 Operation
4.12.3 Revenue Structure
4.12.4 Gross Margin
4.12.5 R and D and Investment
4.12.6 Anticipation and Outlook
4.13 Health BioMed
4.13.1 Profile
4.13.2 Operation
4.13.3 Revenue Structure
4.13.4 Gross Margin
4.13.5 Supply and Marketing
4.13.6 R and D and Investment
4.13.7 Anticipation and Outlook
4.14 Wondfo
4.14.1 Profile
4.14.2 Operation
4.14.3 Revenue Structure
4.14.4 Gross Margin
4.14.5 Supply and Marketing
4.14.6 R and D and Investment
4.14.7 Anticipation and Outlook
4.15 Thalys
4.15.1 Profile
4.15.2 Operation
4.15.3 Revenue Structure
4.15.4 Gross Margin
4.15.5 Production and Marketing
4.15.6 Supply and Marketing
4.15.7 R and D and Investment
4.15.8 Anticipation and Outlook
4.16 SHINVA
4.16.1 Profile
4.16.2 Operation
4.16.3 Gross Margin
4.16.4 Diagnostic Reagent Business
4.17 Humanwell Healthcare
4.17.1 Profile
4.17.2 Operation
4.17.3 Diagnostic Reagent Business

5 Summary and Forecast
5.1 Anticipation and Outlook of China Diagnostic Reagent Industry
5.2 Operation Comparison between Major Companies
5.2.1 Revenue
5.2.2 Net Income
5.2.3 Gross Margin
5.2.4 In Vitro Diagnostics Business


Companies Mentioned
Shanghai Kehua Bio-engineering Co., Ltd. (KHB)
Beijing Strong Biotechnologies, Inc (BSBE)
Da An Gene
Fosun Pharmaceutical
Beijing Leadman Biochemistry Co., Ltd.
Livzon Pharmaceutical Group Inc.
Mindray Medical
Biosino Bio-Technology and Science Inc.
Maker Biotechnology
Sinocare
Beijing Kinghawk Pharmaceutical Co., Ltd.
Bohui Innovation
Health BioMed
Wondfo
Thalys
SHINVA
Humanwell Healthcare

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Competing in the Global Enteric Disease Testing Market

2016 Competing in the Global Enteric Disease Testing Market

  • $ 11500
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $11,500.  DataPack (test volumes, sales forecasts, supplier shares) $7500. This new 389-page report from VPGMarketResearch.com contains 97 tables and provides analysis of the global enteric ...

US Coagulation Testing Market: Hospitals, Commercial Laboratories, POC Locations

US Coagulation Testing Market: Hospitals, Commercial Laboratories, POC Locations

  • $ 7500
  • Industry report
  • July 2016
  • by Venture Planning Group

Complete report $11,500.  DataPack (test volumes, sales forecasts, supplier shares) $7,500. Summary This comprehensive report contains 455 pages, 60 tables, and is designed to help current suppliers and ...

Enteric Diseases: Campylobacter, Cryptosporidium, E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, Vibrio, Yersinia

Enteric Diseases: Campylobacter, Cryptosporidium, E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, Vibrio, Yersinia

  • $ 7500
  • Industry report
  • September 2016
  • by Venture Planning Group

Complete report $11,500.  DataPack (test volumes, sales forecasts, supplier shares) $7500. This new 389-page report from VPGMarketResearch.com contains 97 tables and provides analysis of the global enteric ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.